StemCell Therapy

POWAY, CA--(Marketwire -03/22/12)- Vet-Stem announced today the introduction of StemInsure. The StemInsure service provides banked stem cells that can be grown to supply a lifetime of stem cell therapy for dogs. One fat collection, in conjunction with another anesthetized procedure, gives access to a lifetime of stem cells.

Vet-Stem has trained over 3,500 veterinarians, provided stem cells for over 8,000 animals in the US and Canada and currently banks more than 25,000 doses for future therapeutic use. Many veterinarians and their clients have requested a method to collect and store stem cells when a dog is young, before it needs the regenerative cells for therapy. StemInsure was designed to meet this need.

A Vet-Stem credentialed veterinarian can collect as little as 5 grams of fat (about the size of a grape) from a dog or puppy during an anesthetized procedure. Many veterinarians and owners are electing to do this fat collection in conjunction with a spay or neuter. This small amount of fat is processed and stem cells are cryopreserved in Vet-Stem's state-of-the-art facility. The cells can be cultured in the future to provide enough stem cells to last for the lifetime of the dog. More information can be found at http://www.vet-stem.com/steminsure.php.

"Vet-Stem is pleased to provide StemInsure as a solution to the thousands of veterinarians and dog owners who recognize the value of Vet-Stem cell therapy. The ability to store the cells in conjunction with another procedure is a great way to ensure that the dog will have access to a lifetime of cell therapy while reducing the number of anesthetic events," said Dr. Bob Harman, DVM, MPVM, and CEO of Vet-Stem. Dr. Harman continued, "Currently, Vet-Stem Regenerative Cell Therapy is widely used to treat osteoarthritis, and tendon/ligament injuries. It is our expectation that the therapeutic use of adipose derived stem cells will continue to expand and add to the value of a lifetime supply of stem cells for dogs."

About Vet-Stem:In January of 2004, Vet-Stem introduced the first veterinary stem cell service in the United States. Since that time there has been rapid adoption of this technology for treatment of tendon, ligament, and joint injuries by the veterinary community. Studies have shown that mesenchymal stem cells can dramatically improve the healing of injuries and diseases that have had very few treatment options in the past.

See more here:
Vet-Stem Announces StemInsure(R): A Small Fat Sample Now, a Lifetime of Stem Cells Later

2nd Lee Co. doctor's license restricted in stem cell case

FORT MYERS, Fla.- Another Lee County doctor is caught in the center of a stem cell controversy. The State Department of Health has issued an emergency license restriction to Dr. Konstantine Yankopolus, a general practitioner.

Dr. Yankopolus is still allowed to practice general medicine and is treating patients. The license restriction mandates he can't do anything involving stem cell treatment.

It's business as usual at his office on Colonial Blvd.

The doctor is still treating patients, but an emergency order issued from the Florida Department of Health, Monday prevents him from doing anything with stem cells.

The order says Dr. Yankopolus' license "is hereby immediately restricted from providing, collaborating, facilitating, procuring, referring or advising on any stem cell treatment."

The action comes after the state suspended the license of his colleague, Dr. Zannos Grekos' earlier this month.

The emergency order says Dr. Yankopolus helped Dr. Grekos perform stem cell therapy on the late Richard Polling despite knowing the Bonita Springs cardiologist was not allowed to do such a procedure.

The state Surgeon General alleges, Dr. Yankopolus falsified Polling's records.

He writes, "Subsequent to the death of patient R.P., Dr. Yankopolus entered a false medical progress note in R.P.'s chart falsely indicating that no stem cell preparation was infused."

See the article here:
2nd Lee Co. doctor's license restricted in stem cell case

TUESDAY, March 20 (HealthDay News) -- A novel technique that uses a kidney transplant recipient's own stem cells may someday replace or reduce the initial use of anti-rejection medications, new research suggests.

Six months after receiving a kidney transplant, only about 8 percent of people given their own mesenchymal stem cells experienced rejection compared with almost 22 percent of people on the standard anti-rejection drugs, according to the study.

"Mesenchymal stem cells are stem cells that can be differentiated into a variety of cells," explained Dr. Camillo Ricordi, study senior author and director of the Cell Transplant Center and Diabetes Research Institute at the University of Miami Miller School of Medicine.

"If you infuse mesenchymal stem cells at the time of the transplant, you could replace the use of powerful anti-rejection drugs, and maybe replace immunosuppressants altogether," he said. This technique could be used in the transplantation of islet cells (in the pancreas) for people with type 1 diabetes, and for other organ transplants, such as the liver, he added.

The people given their own stem cells also had improved kidney function earlier after transplant, Ricordi said.

Results of the study appear in the March 21 issue of the Journal of the American Medical Association.

One of the biggest remaining hurdles in organ transplantation remains the need for powerful anti-rejection and immune-suppressing medications after the transplant.

"Basically, the way we prevent kidney rejections is by putting you on very powerful anti-rejection drugs and immunosuppressive agents to prevent your cells from attacking the foreign organ," said Dr. Robert Provenzano, chair of the department of nephrology, hypertension and transplantation at St. John Providence Health System in Detroit. "But, the current standard has some problems, like an increased risk of infections and the possibility of creating a cancer."

The body's immune system sends out surveillance cells to protect the body against foreign invaders, such as a bacteria, virus or, in this case, a new organ, Provenzano said. The current method of preventing these cells from attacking the new organ is essentially to destroy the surveillance cells. But mesenchymal cells can naturally suppress those surveillance cells so they don't attack, he said.

To see if this suppression would be enough to prevent rejection, Ricordi and his colleagues, including researchers from Xiamen University in China, recruited 159 people with serious kidney disease who were on dialysis. They ranged in age from 18 to 61.

See the original post:
Stem Cell Therapy Could Boost Kidney Transplant Success: Study

A special dog used to help people is getting some much-needed help of her own at a Virginia clinic, myFOXdc.com reported.

Red, a 12-year-old black Labrador, is one of the last surviving search and rescue dogs deployed during the 9/11 attacks.

Her handler, Heather Roche, told WTTG-TV that Red was recently certified when Sept. 11, 2001, occurred, and the devastating terror attacks were her first big mission.

Red's job was to find DNA evidence at The Pentagon's north parking lot with 26 other dogs, and according to Roche, she did a "fantastic job."

"I got her as a puppy ... You have to convince [her] everything that she does, whether it's climbing ladders or any kind of search, that it's her idea," Roche told WTTG-TV. "No matter what I've asked her to do, she's done it and she's done it flawlessly."

But in her old age Red developed crippling arthritis, and underwent stem cell regenerative therapy Monday to help ease her pain so she can get back out on the job.

Dr. John Herrity of Burke Animal Clinic in Burke, Va., told WTTG-TV, "Red has a back issue that, after a fall from a ladder has not really been right, and has been living in pain, so we're going to give those stem cells IV [intravenously] and then also inject them along the back to try to help Red's comfort."

"She's had a great career and has made a difference to a lot of families by bringing their loved ones home," Roche said.

Click here to read more.

See original here:
9/11 search and rescue dog receives stem cell therapy

MOUNTAIN VIEW, Calif., March 20, 2012 /PRNewswire/ -- SanBio Inc. today announced the successful enrollment of the first dose cohort of patients in its Phase 1/2a clinical trial testing the safety and efficacy of a novel allogeneic stem cell therapy product, SB623, in patients suffering from chronic deficits resulting from previous stroke injuries. The first 6 patients, of a total of 18, have been successfully administered SB623. The trial is being conducted at Stanford University and the University of Pittsburgh. No safety concerns have been reported. For details regarding this clinical trial, please refer to http://www.strokeclinicaltrial.org.

SB623 is derived from adult bone marrow and has shown safety and efficacy in rodent models of chronic stroke. "This represents a major milestone in the human clinical testing of this important new approach for regenerative medicine", said Keita Mori, SanBio CEO. "We are pleased to learn that the initial dose level was well tolerated."

SB623 is being delivered to the damaged region of the brains of patients who have suffered an ischemic stroke. Product safety is the primary focus of the study but various measurements of efficacy are also being tested.

"The successful completion of the initial dose cohort is a major step in any first-in-human study", said Dr. Ernest Yankee, SanBio's Vice President of Development. "We are looking forward to initiating the next two dose cohorts and wrapping up the study. The safety findings thus far are very encouraging"

About SB623: SB623 is a proprietary cell therapy product consisting of cells derived from genetically engineered bone marrow stromal cells obtained from healthy adult donors. SB623 is administered adjacent to the area damaged by stroke and functions by producing proteins that aid the regenerative process.

About SanBio: SanBio is a privately held San Francisco Bay Area biotechnology company focused on the discovery and development of new regenerative cell therapy products.

For more information: http://www.san-bio.com

See more here:
SanBio Announces Enrollment of First Cohort of Patients in Its Clinical Trial of Stem Cell Therapy for Chronic Stroke

09-02-2012 23:02 Stem Cell Therapy latest news - Jan 2012, MS options Contact Kevin for help to raise funds for treatment part 2 of 4

The rest is here:
Stem Cells Therapy MS2.mp4 - Video

14-03-2012 16:22 Stem Cells for Cosmetic use using Bioplasty featuring Artefill. Envision using your own stem cells to restore or reshape your body to a more attractive and youthful figure in a way that is safe, natural and undetectable. Today, stem cell therapy is no longer a science fiction story but a reality...

Continued here:
Bioplasty - Stem Cell Treatments

Dr. Konstantine K. Yankopolus

The state Department of Health restricted a second doctor's license for working under the direction of Dr. Zannos Grekos in performing a stem cell treatment and for falsifying a medical report after a patient died, according to the state order.

The emergency license restriction is against Dr. Konstantine K. Yankopolus, 3880 Colonial Blvd., Suite 2, Fort Myers, according to the order issued by the state health department late Monday.

The restriction only prohibits Yankopolus from doing anything with stem cells. After a career as an obstetrician/gynecologist, he is now in general practice.

"We attempted a life-saving procedure on a very sick patient and it didn't go well," Yankopolus said Monday night. "Our motivation was pure the patient had no other option."

The state's action comes on the heels of Grekos attorney last week issuing a statement that another doctor, and not his client, was involved in the treatment of a 77-year-old Indiana man who died March 2. Grekos attorney also denied that a stem cell treatment was performed, only liposuction.

The state health department suspended Grekos license after the death, saying Grekos violated an earlier restriction that he not to do anything with stem cells or bone marrow aspirate in his practice at 9500 Bonita Beach Road, Suite 310.

Lee County sheriff's authorities identified the man as Richard Poling, of Newburgh, Ind. The Sheriff's Office also is conducting a criminal probe.

Grekos has been under state scrutiny by state health regulators for well over a year when an earlier patient, a 66-year-old breast cancer patient, went to him for stem cell treatment in 2010 for neurological problems. She later fell, suffered severe brain damage and was taken off life support. After her death, the state ordered Grekos not to do anything with stem cells or bone marrow aspirate in his practice.

The restriction did not prohibit him from conducting educational seminars in the community about stem cell therapy or from arranging for patients to go for the treatment in the Dominican Republic.

Excerpt from:
State: Second doctor's license restricted for performing stem cell treatment on patient who died

Editor's Choice Academic Journal Main Category: Huntingtons Disease Also Included In: Stem Cell Research Article Date: 19 Mar 2012 - 10:00 PDT

email to a friend printer friendly opinions

Current Article Ratings:

4 (1 votes)

3 (1 votes)

However, according to a study published March 15 in the journal Cell Stem Cell, a special type of brain cell created from stem cells could help restore the muscle coordination deficits that are responsible for uncontrollable spasms, a characteristic of the disease. The researchers demonstrated that movement in mice with a Huntington's-like condition could be restored.

Su-Chun Zhang, a University of Wisconsin-Madison neuroscientist and the senior author of the study, said:

In the study Zhang, who is an expert in creating various types of brain cells from human embryonic or induce pluripotent stem cells, and his team focused on GABA neurons. The degradation of GABA cells causes the breakdown of a vital neural circuit and loss of motor function in individuals suffering from Huntington's disease.

According to Zhang, GABA neurons generate a vital neurotransmitter, a chemical that helps support the communication network in the brain that coordinates movement.

Zhang and his team at the UW-Madison Waisman Center, discovered how to generate large quantities of GABA neurons from human embryonic stem cells. The team's goal was to determine whether these cells would safely integrate into the brain of a mouse model of Huntington's disease.

Read the original post:
Huntington's Disease - Stem Cell Therapy Potential

Stem Cell Therapy Helping Heroic Dogs Recover

News4's Darcy Spencer explains how a breakthrough treatment is helping search and rescue dogs like Red recover after years of working in disaster zones.

A breakthrough treatment is helping area search-and-rescue dogs that played key roles on Sept. 11, 2001, and during other disasters.

Red's first assignment as a search, rescue and recovery dog was at the Pentagon following the 9/11 attacks. Years of rescue work and a 12-foot fall from a ladder have taken a toll. Arthritis forced Red into retirement in July and turned her into a couch potato.

The 12-year-old black lab received a breakthrough stem cell treatment today that will ease her pain and give her more mobility.

Her veterinarian, Dr. John Herrity, of the Burke Animal Clinic, has done more than two dozen of the stem cell operations developed by Medivet America, which also donated the cost of the procedure.

The treatment won't bring Red back out of retirement, but it is expected to put spring back in her step within a couple of months.

Two other 9/11 search-and-rescued dogs have been treated with stem cell therapy and are back to their normal activities.

See the article here:
Hero Dog Receives Stem Cell Therapy

(MENAFN - Arab Times) Ministry of Health (MoH) employees holding PhD degrees announced that they will participate in the sit-in demonstration carried out by the Labor Union of Health Ministry, reports Al-Seyassah daily.

In the press release, they said they are protesting against the fact that they are receiving the same salary scale and benefits as any other ministry employee with lower qualifications and if necessary, they are ready to even burn their PhD certificates at the sit-in to get the benefits they deserve according to their qualifications.

The sit-in will be carried out in front of Health Ministry headquarters in Sulaibikhat at 10 am on Tuesday, March 20, 2012.

The number of PhD holders has exceeded 100 considering the participation of PhD holders from other ministries as well.

Meanwhile, the MoH has banned stem cell therapy in the country until the committee tasked to set the standards for the treatment completes its work, reports Al-Anba daily quoting Director of Health License Department Dr Marzouq Al-Bader.

Al-Bader disclosed the ministry had earlier formed the committee to ensure the stem cell procedures are carried out in an appropriate manner to protect the patients. He added the ministry will also issue a decision soon to regulate the use of antibiotics in the private health sector.

Meanwhile, Al-Bader confirmed the ministry has endorsed around 51,000 female doctors in private hospitals and health centers. He said the ministry closely monitors the performance of female doctors and those found to have violated the law will be referred to the Medical Council for the necessary action.

On the issuance of licenses through the Internet, Al-Bader revealed his department has asked the ministry to activate the e-link system for this purpose.

He said the ministry has asked the Kuwait Municipality to issue permit for the construction of a building fit for the department's operations.

Meanwhile, the Medical Emergency Department at the Ministry of Health has affirmed its readiness to deal with emergency cases that may arise due to a series of dust storms engulfing the country.

See more here:
Stem cell therapy banned in Kuwait

Source:
http://intlstemcell.blogspot.com/feeds/posts/default?alt=rss

Stem cell researchers and institutions throughout the state are likely to be affected by proposed changes – to be discussed online publicly Tuesday – dealing with how the California stem cell agency will handle its $3 billion in grants.

An important online session – open to all interested parties – comes up then, but advance registration is required.

The proposals are wide-ranging and detailed. The nearly 500 recipients of CIRM grants should examine them closely in addition to any persons seriously interested in California stem cell affairs. The changes deal with such subjects as milestones for research grants, indirect costs, travel costs, withholding payments for failure to file a progress report and much, much more.

Here is a link to the main page for all this, which has instructions on how to register for the online session along with links to the changes and their rationale.

(Editor's note: This item was filed from the Rio Sabana in the Darien in Panama when we found a weak Internet cellular link. We are still underway so postings are unlikely between now and later this month.)

Source:
http://californiastemcellreport.blogspot.com/feeds/posts/default?alt=rss

Source:
http://intlstemcell.blogspot.com/feeds/posts/default?alt=rss

Stem cell researchers and institutions throughout the state are likely to be affected by proposed changes – to be discussed online publicly Tuesday – dealing with how the California stem cell agency will handle its $3 billion in grants.

An important online session – open to all interested parties – comes up then, but advance registration is required.

The proposals are wide-ranging and detailed. The nearly 500 recipients of CIRM grants should examine them closely in addition to any persons seriously interested in California stem cell affairs. The changes deal with such subjects as milestones for research grants, indirect costs, travel costs, withholding payments for failure to file a progress report and much, much more.

Here is a link to the main page for all this, which has instructions on how to register for the online session along with links to the changes and their rationale.

(Editor's note: This item was filed from the Rio Sabana in the Darien in Panama when we found a weak Internet cellular link. We are still underway so postings are unlikely between now and later this month.)

Source:
http://californiastemcellreport.blogspot.com/feeds/posts/default?alt=rss

A NEW stem cell therapy treatment to develop new bones for patients with bone loss and new skin for recipients of plastic surgery has been developed, doctors from Shanghai No.9 People's Hospital announced yesterday.

In the procedure, medical staff use a special machine to collect stem cells from a patient's blood. The stem cells adhere to a base made of a special biological material.

The stem cells are then transplanted into the patient's body, where they grow into either new bones or skin tissue, while the base is absorbed by the human body.

"So far the practice has been successful in treating patients with bone and skin loss," said Dr Dai Kerong from Shanghai Jiao Tong University's translational medicine institute at Shanghai No.9 hospital. "The stem cell technology will be used to develop corneas for blind people as well as treating heart attack and stroke patients by developing new heart and cerebral tissue."

The technology is patented in China and abroad and will be licensed within one or two years, according to Dai.

China has established 51 translational medicine centers to boost the introduction of laboratory research into clinical use.

The complicated procedures and documentation required often prevent doctors from introducing lab success into clinical practice.

Dai said one reagent developed by No. 9 hospital's doctors for in vitro fertilization received a license in Europe within six months and has been used in clinical practice "while this would take at least five years in China."

Read this article:
Eastday-Big stem cell breakthrough

Public release date: 15-Mar-2012 [ | E-mail | Share ]

Contact: Jennifer Ganton jganton@ohri.ca 613-798-5555 x73325 Ottawa Hospital Research Institute

A team of researchers from the Ottawa Hospital Research Institute (OHRI) and the University of Ottawa (uOttawa) has been awarded $367,000 from the Canadian Institutes of Health Research (CIHR) and $75,000 from the Stem Cell Network to lead the first clinical trial in the world of a stem cell therapy for septic shock. This deadly condition occurs when an infection spreads throughout the body and over-activates the immune system, resulting in severe organ damage and death in 30 to 40 per cent of cases. Septic shock accounts for 20 per cent of all Intensive Care Unit (ICU) admissions in Canada and costs $4 billion annually. Under the leadership of Dr. Lauralyn McIntyre, this new "Phase I" trial will test the experimental therapy in up to 15 patients with septic shock at The Ottawa Hospital's ICU.

The treatment involves mesenchymal stem cells, also called mesenchymal stromal cells or MSCs. Like other stem cells, they can give rise to a variety of more specialized cells and tissues and can help repair and regenerate damaged organs. They also have a unique ability to modify the body's immune response and enhance the clearance of infectious organisms. They can be found in adult bone marrow and other tissues, as well as umbilical cord blood, and they seem to be easily transplantable between people, because they are more able to avoid immune rejection.

There has been a great deal of interest in using MSCs to treat disease, with most research so far focused on heart disease, stroke, inflammatory bowel disease and blood cancers. Hundreds of patients with these diseases have already been treated with MSCs through clinical trials, with results suggesting that these cells are safe in these patients, and have promising signs of effectiveness. MSCs are still considered experimental however, and have not been approved by Health Canada as a standard therapy for any disease.

In recent years, a number of animal studies have suggested that MSCs may also be able to help treat septic shock. For example, a recent study by Dr. Duncan Stewart, CEO and Scientific Director of OHRI (and also a co-investigator on the new clinical trial) showed that treatment with these cells can triple survival in a mouse model of this condition.

"Mesenchymal stem cell therapy appears promising in animal studies, but it will require many years of clinical trials involving hundreds of patients to know if it is safe and effective," said Dr. Lauralyn McIntyre, a Scientist at the OHRI, ICU Physician at The Ottawa Hospital, Assistant Professor of Medicine at uOttawa and a New Investigator with CIHR and Canadian Blood Services. "This trial is a first step, but it is a very exciting first step."

As with all "Phase I" trials, the main goal of this study is to evaluate the safety of the therapy and determine the best dose for future studies. The 15 patients in the treatment group will receive standard treatments (such as fluids, antibiotics and blood pressure control), plus a planned intravenous dose of 0.3 to 3 million MSCs per kg of body weight. The MSCs will be obtained from the bone marrow of healthy donors and purified in the OHRI's Good Manufacturing Practice Laboratory in the Sprott Centre for Stem Cell Research. The researchers also plan to evaluate 24 similar septic shock patients who will receive standard treatments only (no MSCs). All patients will be rigorously monitored for side effects, and blood samples will be taken at specific time points to monitor the cells and their activity. This trial will not be randomized or blinded and it will not include enough patients to reliably determine if the therapy is effective. It will be conducted under the supervision of Health Canada and the Ottawa Hospital Research Ethics Board, and will have to be approved by both of these organizations before commencing.

"The OHRI is rapidly becoming known as a leader in conducting world-first clinical trials with innovative therapies such as stem cells," said Dr. Duncan Stewart, CEO and Scientific Director of OHRI, Vice-President of Research at The Ottawa Hospital and Professor of Medicine at uOttawa. "This research is truly pushing the boundaries of medical science forward, and is providing the citizens of Ottawa with access to promising new therapies."

"The Canadian Institutes of Health Research (CIHR) is very pleased to support this clinical trial," said Dr. Jean Rouleau, Scientific Director of the CIHR Institute of Circulatory and Respiratory Health. "The work of Dr. McIntyre and her colleagues will not only add to our growing knowledge of the benefits of stem-cell therapies, but will hopefully lead to treatments that can help save the lives of patients where currently, our treatment options are less than optimal."

Link:
Ottawa researchers to lead world-first clinical trial of stem cell therapy for septic shock

EDMONDS, Wash., March 14, 2012 /PRNewswire/ --Washington Center for Pain Management is participating in a nationwide FDA-cleared adult stem cell study testing novel treatment for chronic low back pain and has enrolled its first patient. The study will test the use of Mesenchymal Precursor Cells (MPCs) adult stem cells derived from bone marrow that will be directly injected into the lumbar disc. The minimally invasive procedure may offer an alternative to back surgery for eligible patients with chronic pain from degenerative discs.

An estimated 30 million people in the United States suffer from back pain. Degenerative disc disease is the most common cause of low-back pain, which develops with the gradual loss of a material called proteoglycan, which cushions the bones of the spine and enables normal motion.

Most patients with low-back pain respond to physical therapy and medications, but in advanced cases, artificial disc replacement or spinal fusion -- removal of the degenerated discs and the fusion of the bones of the spine -- is necessary. However, these surgeries often are not entirely effective.

"Millions of Americans are debilitated by chronic low back pain," says Dr Hyun Joong Hong MD, the lead investigator at The Washington Center for Pain Management. "This promising therapy is at the cutting edge of medical science and has the potential to create a paradigm shift in our approach to minimally invasive solutions to this disease."

Researchers will enroll approximately 100 study participants. About fifteen participants will be enrolled at The Washington Center for Pain Management and the rest at 11 other medical centers throughout the United States. The trial is scheduled to last for three years.

Washington Center for Pain Management is enrolling study participants suffering from moderate low-back pain for a minimum of six months and whose condition has not responded to other, conventional treatments.

Once enrolled, patients are randomly assigned to one of four treatment groups:

Patients will receive a single injection of their assigned test agent directly into the center of the target discs within their spine and will be monitored for safety. Patients will also be monitored using imaging to identify any changes in their disease condition or disease progression. Use of pain medications, self-reports of pain, subsequent surgical interventions and assessments of disability, quality of life, productivity and activity will be evaluated. Repair of the disc and reduction of chronic back pain will be assessed in each patient.

Promising results have been observed in prior research using animal models when stem cells were investigated for the repair of damaged spine discs. The cells were well tolerated in these study animals.

This study is sponsored by Mesoblast Limited, a world leader in the development of biologic products for the broad field of regenerative medicine. Mesoblast has the worldwide exclusive rights to a series of patents and technologies developed over more than 10 years relating to the identification, extraction, culture and uses of adult Mesenchymal Precursor Cells (MPCs). The MPCs are derived from young adult donors' bone marrow and are immune tolerant.

See original here:
Washington Center for Pain Management Begins Enrollment in United States Stem Cell Therapy Study in Subjects With ...

09-03-2012 18:23 A company is locked in a battle with the FDA over the use one's own stem cells. The company argues that one has the right to over one's own body? If that's true, why is the FDA blocking this treatment? Find out. Plus, doctors are refusing to treat children that do not get vaccinated. Is this ethical? See more at http://www.pjtv.com

More here:
FDA Blocks Stem Cell Therapy: Is the Government Playing a Cell Game? - Video

Source:
http://intlstemcell.blogspot.com/feeds/posts/default?alt=rss